halothane and am-356

halothane has been researched along with am-356 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bedoya, M; Decher, N; González, W; Kiper, AK; Ramírez, D; Rinné, S	1
Honoré, E; Lazdunski, M; Maingret, F; Patel, AJ	1
Anetseder, M; Berkowitz, C; Eberhart, L; Eckenhoff, R; Hanley, PJ; Preisig-Müller, R; Putzke, C; Rinné, S; Schlichthörl, G; Vassiliou, T; Wulf, H	1

Reviews

1 review(s) available for halothane and am-356

Article	Year
TASK Channels Pharmacology: New Challenges in Drug Design. Journal of medicinal chemistry, 2019, 11-27, Volume: 62, Issue:22 Topics: Animals; Drug Design; Drug Discovery; Humans; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Tandem Pore Domain	2019

Other Studies

2 other study(ies) available for halothane and am-356

Article	Year
The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. The EMBO journal, 2001, Jan-15, Volume: 20, Issue:1-2 Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Cerebellum; Chlorocebus aethiops; COS Cells; Endocannabinoids; Halothane; Humans; Membrane Potentials; Mice; Motor Neurons; Nerve Tissue Proteins; Neurons; Piperidines; Polyunsaturated Alkamides; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Tandem Pore Domain; Pyrazoles; Rats; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug; Recombinant Proteins; Rimonabant; Transfection	2001
Differential effects of volatile and intravenous anesthetics on the activity of human TASK-1. American journal of physiology. Cell physiology, 2007, Volume: 293, Issue:4 Topics: Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Arachidonic Acids; Cells, Cultured; Dose-Response Relationship, Drug; Etomidate; Halothane; Humans; Hydrogen-Ion Concentration; Isoflurane; Membrane Potentials; Methyl Ethers; Myocytes, Cardiac; Nerve Tissue Proteins; Oocytes; Patch-Clamp Techniques; Potassium; Potassium Channel Blockers; Potassium Channels, Tandem Pore Domain; Propofol; Rats; RNA, Complementary; Sevoflurane; Xenopus laevis	2007

Article

Year

The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1.

The EMBO journal, 2001, Jan-15, Volume: 20, Issue:1-2

Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Cerebellum; Chlorocebus aethiops; COS Cells; Endocannabinoids; Halothane; Humans; Membrane Potentials; Mice; Motor Neurons; Nerve Tissue Proteins; Neurons; Piperidines; Polyunsaturated Alkamides; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Tandem Pore Domain; Pyrazoles; Rats; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug; Recombinant Proteins; Rimonabant; Transfection

2001

Differential effects of volatile and intravenous anesthetics on the activity of human TASK-1.

American journal of physiology. Cell physiology, 2007, Volume: 293, Issue:4

Topics: Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Arachidonic Acids; Cells, Cultured; Dose-Response Relationship, Drug; Etomidate; Halothane; Humans; Hydrogen-Ion Concentration; Isoflurane; Membrane Potentials; Methyl Ethers; Myocytes, Cardiac; Nerve Tissue Proteins; Oocytes; Patch-Clamp Techniques; Potassium; Potassium Channel Blockers; Potassium Channels, Tandem Pore Domain; Propofol; Rats; RNA, Complementary; Sevoflurane; Xenopus laevis

2007